Soligenix, Inc. Common Stock (SNGX) Stock: What Does the Chart Say Thursday?

Soligenix, Inc. Common Stock (SNGX) stock has gained 223.81% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Soligenix, Inc. Common Stock has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on SNGX!

See Full SNGX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With SNGX Stock Today?

Soligenix, Inc. Common Stock (SNGX) stock has gained 227.4% while the S&P 500 is lower by -0.07% as of 2:04 PM on Thursday, Nov 30. SNGX has gained $0.94 from the previous closing price of $0.42 on volume of 80,224,383 shares. Over the past year the S&P 500 has gained 14.90% while SNGX is lower by -84.19%. SNGX lost -$2.04 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Soligenix, Inc. Common Stock click here.

More About Soligenix, Inc. Common Stock

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). Click Here to get the full Stock Report for Soligenix, Inc. Common Stock stock.